Beta · Literature search and summary
Ingredients, label cautions and kidney-related evidence.
51 products · Select a product for label details
DIN 02074702 · Sanofi Consumer Health Inc.. Health Canada status: Marketed; status date: November 19, 2011. The indexed record does not confirm current pharmacy stock. Keep separate from US lidocaine products and earlier cancelled DINs.
The Canadian manufacturer lists no NSAID or salicylate in this gel. Check other Biofreeze formulations separately.
NPN 01914634. Menthol is the sole listed medicinal ingredient. Trolamine is listed as non-medicinal; it is not trolamine salicylate.
The Mentholatum Company of Canada, Limited, n.d.
Local anaesthetic. Ingredient listing verified; full dosing and renal review not included.
This patch lists methyl salicylate. The registry entry does not provide its strength; check the package.
Contains methyl salicylate; check the exact formulation within this brand.
The cream belongs in the salicylate group.
Contains two NSAIDs. Exact-combination exposure is not established; confirm composition with the dispensing pharmacy.
Brochure formulation: Ketoprofen 7%; diclofenac 3%; amitriptyline 3%; baclofen 10%; lidocaine 4%; menthol 0.15%; camphor 0.15%. Percentage basis and salt details require pharmacy confirmation. InflaFlex, n.d.
Base: Proprietary transdermal emulsion base; composition undisclosed. InflaFlex, n.d.
Renal precautions: No product-specific PK data or guidance on renal contraindications, dose adjustment or monitoring was identified in this review. Exposure cannot be estimated from commercial gels or summed NSAID percentages. Review the other active ingredients separately. InflaFlex, n.d.
Verified against the Canadian manufacturer’s 400 g page. MSM is medicinal; hemp seed oil is non-medicinal. Verify other creams, gels, foams and sprays separately. No product-specific exposure estimate was identified.
Contains methyl salicylate alongside hemp seed oil. Verify the separate 6x cream, gel, foam and spray individually.
The manufacturer calls the ingredient Capsicum annuum; no additional capsaicin standardization is inferred. Verify other topical variants separately.
Verified for this cream only. Other formulations and comparative efficacy were not assessed.
The handout calls this methyl salicylate. Trolamine salicylate and triethanolamine salicylate are names for the same ingredient. The DPD resolves conflicting duplicate text on the Extra Strength manufacturer page.
2017 Canadian record: Lavender essential oil 20% (w/w); geranium essential oil 21% (w/w); bergamot essential oil 10% (w/w); eucalyptus essential oil 11% (w/w); tea tree essential oil 10% (w/w). Homeopathic ingredients, each 12C: Aconitum napellus, Hypericum perforatum, Lycopodium clavatum, Phosphorus, Rhus toxicodendron, Secale cornutum. Health Canada, 2017a
NPN 80039423. Health Canada’s September 2017 extract listed this licence as Active. Current formulation and market status remain unconfirmed; no discontinuation record was verified.
Product source for Neuragen · Gel2017 Canadian record: Lavender essential oil 28% (v/v); geranium essential oil 28% (v/v); bergamot essential oil 14% (v/v); eucalyptus essential oil 14% (v/v); tea tree essential oil 14% (v/v). Homeopathic ingredients, each 12C: Aconitum napellus, Hypericum perforatum, Lycopodium clavatum, Phosphorus, Rhus toxicodendron, Secale cornutum. Health Canada, 2017a
NPN 80039462. Health Canada’s September 2017 extract listed this licence as Active. Current formulation and market status remain unconfirmed; no discontinuation record was verified.
Canadian retailer listing: Lavender and geranium oils 28.29% v/v each; bergamot, eucalyptus and tea tree oils 14.14% v/v each. These differ from the 28% (v/v) and 14% (v/v) values in the 2017 extract. Pharmacy For Life, n.d. Health Canada, 2017a
Comparison: Both list the same six homeopathic ingredients at 12C. The difference in reported precision does not establish reformulation. The retailer text has no label revision date and is not a confirmed current Canadian label. Pharmacy For Life, n.d. Health Canada, 2017a
Product source for Neuragen · Oil2017 Canadian record: Lavender essential oil 6% (w/w); geranium essential oil 6% (w/w); bergamot essential oil 3% (w/w); eucalyptus essential oil 3% (w/w); tea tree essential oil 3% (w/w). Homeopathic ingredients, each 12C: Aconitum napellus, Hypericum perforatum, Lycopodium clavatum, Phosphore, Rhus toxicodendron, Secale cornutum. Health Canada, 2017a
NPN 80049085. Health Canada’s September 2017 extract listed this licence as Active. Current formulation and market status remain unconfirmed; no discontinuation record was verified.
Product source for Neuragen · Pain Relief Cream50 drops per knee 3 times daily OR 40 drops per knee 4 times daily; maximum treatment duration 3 months, continuous or intermittent. Knight Therapeutics Inc., 2025
Adults ≥18; pediatric use contraindicated. Lower starting dose may be considered for older/frail patients under close supervision; no numerical reduction supplied. Knight Therapeutics Inc., 2025
Studied application: 40 drops (approximately 1.2 mL) to EACH knee four times daily Holt et al., 2015
Site / area: Both knees; front, back and sides · Area not reported Holt et al., 2015
Healthy adults aged 18–55; randomized open crossover · 7.5 days; steady-state results on day 8.
Oral comparator: Sandoz diclofenac sodium: methods say delayed-release; Table 4 says SR (sustained release). Unresolved source inconsistency. 75 mg twice daily. Holt et al., 2015
Study context, not dosing advice. These results do not establish kidney safety or equivalent pain relief.
Study details and exposure comparisonKnight Therapeutics Inc., 2025
Its Canadian renal contraindications differ from those of Voltaren; review the exact label.
Non-medicinal ingredients: Dimethyl sulfoxide (DMSO), ethanol, glycerine, propylene glycol, purified water. The current Canadian composition table does not quantify DMSO. Knight Therapeutics Inc., 2025
Renal precautions: Explicit contraindication: severely impaired or deteriorating renal function (creatinine clearance <30 mL/min). Known hyperkalemia is also contraindicated. Lesser impairment requires monitoring. Consider lower doses with great caution in impaired renal function; no numerical renal adjustment. Consider SCr, CrCl, urea and electrolytes including potassium; periodic monitoring in those at hyperkalemia risk. Reduced perfusion/volume, heart failure, liver dysfunction, diuretics and older age increase concern. CrCl <60 mL/min (or 1 mL/sec) appears as a cardiovascular/renal risk factor, not as an additional absolute contraindication. Knight Therapeutics Inc., 2025
Church & Dwight Canada Corp., n.d.-a
Contains methyl salicylate as well as arnica.
Church & Dwight Canada Corp., n.d.-b
The handout groups this under methyl salicylate. The current Canadian roll-on lists triethanolamine salicylate.
Church & Dwight Canada Corp., n.d.-c
No NSAID or salicylate listed for this exact patch. Check other Rub·A535 patches separately.
Church & Dwight Canada Corp., n.d.-d
No NSAID or salicylate listed among the medicinal ingredients.
Church & Dwight Canada Corp., n.d.-e
Different from Injury Ice Relief Gel.
Church & Dwight Canada Corp., n.d.-i
Contains triethanolamine salicylate despite the “No Odour” name.
Church & Dwight Canada Corp., n.d.-k
Formerly shown on the manufacturer’s Natural Source Arnica page. The current listing is Sensitive Cream; ingredient identity does not establish effectiveness or CKD safety.
Hisamitsu America, Inc., n.d.-a
Separate from the Original and HOT patches.
Hisamitsu America, Inc., n.d.-d
Additional formulation missing from the handout.
Hisamitsu America, Inc., n.d.-b
No NSAID or salicylate listed for this exact patch. Contains natural rubber latex.
Hisamitsu America, Inc., n.d.-c
Canadian labelled uses are minor skin pain and itching; benefit for joint or neuropathic pain is not established by this listing. Do not use in large quantities or over a large body area.
Hisamitsu America, Inc., n.d.-e
The handout calls Salonpas trolamine salicylate. The current individual product page lists methyl salicylate. Older comparison pages show different strengths; match the actual package.
Hisamitsu America, Inc., n.d.-f
Canadian labelled uses are minor skin pain and itching; benefit for joint or neuropathic pain is not established by this listing. Do not use in large quantities or over a large body area.
Haw Par Healthcare Limited, n.d.-a
Match the exact Canadian formulation. The brand includes both salicylate and other products.
Haw Par Healthcare Limited, n.d.-b
Contains capsicum extract; the listed extract mass is not the capsaicin mass.
Haw Par Healthcare Limited, n.d.-c
Match the exact Canadian formulation. The brand includes both salicylate and other products.
Haw Par Healthcare Limited, n.d.-d
Match the exact Canadian formulation. The brand includes both salicylate and other products.
Haw Par Healthcare Limited, n.d.-e
Canadian White / Regular Strength ointment. The manufacturer lists these ingredients together without distinguishing medicinal from non-medicinal ingredients on this page. Keep this formulation separate from Red, Ultra Strength and Muscle & Tension Lotion.
2 g in the morning and 2 g in the evening; maximum 4 g/day over ALL affected areas. Beyond 7 days only if recommended by a doctor. Haleon Canada ULC, 2026b
Indication for adults 18–65 years; no authorized indication for >65 years or <18 years. This is distinct from a contraindication. Haleon Canada ULC, 2026b
Studied application: 2 g twice daily Haleon Canada ULC, 2026b
Site / area: Same ankle · ≈400 cm² Haleon Canada ULC, 2026b
Healthy men and women; randomized open crossover · 7 days; day-7 assessment.
Oral comparator: Voltaren diclofenac sodium 50 mg tablet; release type not specified in the retrieved VOPO summary. 50 mg three times daily. Haleon Canada ULC, 2026b
Study context, not dosing advice. These results do not establish kidney safety or equivalent pain relief.
Study details and exposure comparisonCanadian extra-strength gel. Its labeled regimen and exposure records remain separate from Regular Strength.
Non-medicinal ingredients: Butylhydroxytoluene, carbomer, cocoyl caprylocaprate, diethylamine, fragrance, isopropyl alcohol, liquid paraffin, macrogol cetostearyl ether, oleyl alcohol, propylene glycol, purified water. Haleon Canada ULC, 2026b
Renal precautions: No explicit numeric renal contraindication or renal dose adjustment identified in this monograph. The monograph does not require laboratory monitoring for response or adverse reactions and describes renal-impairment effects on PK as unlikely to be clinically significant. No dedicated CKD/post-AKI PK study is supplied. Large-area/prolonged use may increase systemic effects. Haleon Canada ULC, 2026b
2–4 g for approximately 400–800 cm², 3–4 times daily; no more than 4 applications in 24 h. Beyond 7 days only if recommended by a doctor. Haleon Canada ULC, 2026a
Adults and adolescents ≥16 years; usual adult dosage in geriatrics. Haleon Canada ULC, 2026a
Studied application: 4 g three times daily Haleon Canada ULC, 2026a
Site / area: Not reported Haleon Canada ULC, 2026a
Healthy volunteers; randomized open 3-way crossover · 7 days; final morning administration on day 7.
Oral comparator: Voltaren diclofenac sodium enteric-coated tablet. 25 mg three times daily. Haleon Canada ULC, 2026a
Study context, not dosing advice. These results do not establish kidney safety or equivalent pain relief.
Study details and exposure comparisonCanadian regular-strength gel. Its labeled regimen and exposure records remain separate from Extra Strength.
Non-medicinal ingredients: Carbomer, cocoyl caprylocaprate, diethylamine, fragrance (containing benzyl benzoate), isopropyl alcohol, liquid paraffin, macrogol cetostearyl ether, propylene glycol, purified water. Haleon Canada ULC, 2026a
Renal precautions: No explicit numeric renal contraindication or renal dose adjustment identified in this monograph. The monograph does not require laboratory monitoring for response or adverse reactions and describes renal-impairment effects on PK as unlikely to be clinically significant. These are label statements, not findings from a dedicated CKD or post-AKI trial. Large-area/prolonged use may increase systemic effects. Renal failure reports also appear in the overdosage section. Haleon Canada ULC, 2026a
No NSAID or salicylate listed. Regular Zostrix is a separate formulation; check its strength.
Try a shorter name or choose All products.